 |
|
|
| |
Do resistance associated substitutions (RAS) or Ribavirin (RBV) use influence treatment success of Sofosbuvir (SOF)/Velpatasvir (VEL) in chronic hepatitis C genotype 3 (GT 3) infection? - Results from the GErman hepatitis C COhort (GECCO)
|
| |
| |
Reported by Jules Levin
AASLD: The Liver Meeting 2017; Washington, DC, USA; October 20-24, 2017.
Christensen S1, Ingiliz P2, Mauss S3, Hueppe D4, Baumgarten A2, Schmutz G3, Simon KG5, Berger F3, Busch HW1, Daeumer M6, Schewe K7, Rockstroh JK8, Lutz T9, Timm J10, Von Felden J11, Schulze zur Wiesch J11, for the GECCO study group
1CIM Infectious Diseases, Muenster, Germany. 2Center for Infectiology Berlin (CIB), Berlin, Germany; 3Center for HIV and Hepatogastroenterology, Duesseldorf, Germany; 4Practice for Gastroenterology Herne, Herne, Germany; 5Practice for Gastroenterology Leverkusen, Leverkusen; 6Immungenetik Kaiserslautern, Kaiserslautern, Germany; 7Infektionsmedizinisches Centrum Hamburg, Hamburg, Germany; 8University Hospital Bonn, Bonn, Germany; 6Infektiologikum, Frankfurt, Germany; 11Institut fuer Virologie, Universitaetsklinikum Duesseldorf, Duesseldorf, Germany Ambulanzzentrum Virushepatologie Universitaetsklinikum Hamburg-Eppendorf, Hamburg, Germany.
|
| |
|
|
|
|
|
